Coagulation diagnostics play a critical role in modern healthcare, underpinning essential tests such as prothrombin time (PT), activated partial thromboplastin time (aPTT), and anticoagulant monitoring. These assays form part of the broader in vitro diagnostics (IVD) landscape, alongside related applications such as coagulase assays, which detect bacterial coagulase enzyme activity to differentiate organisms, most notably in the identification of coagulase-positive Staphylococcus aureus infections. Together, these biologically derived diagnostic tools continue to play an expanding role in disease detection and patient management.
However, the industry is facing mounting pressure. The COVID-19 pandemic exposed significant vulnerabilities in global IVD supply chains, including shortages of critical reagents and materials that reduced testing capacity and disrupted diagnostic workflows. At the same time, global regulatory requirements, such as the FDA’s IVD Regulation and the EU’s In Vitro Diagnostic Regulation (IVDR), are becoming more stringent. Regulatory bodies are increasingly introducing reinforced requirements for performance, safety, transparency, and traceability, alongside extensive technical documentation obligations for manufacturers. These challenges are compounded by the industry’s reliance on a limited pool of suppliers, which further increases exposure to shortages and variability.
For coagulation reagents, manufacturing disruptions and cold-chain failures pose a critical challenge, interrupting validation studies, lot qualification, and manufacturing timelines. Since reliable assay performance depends on consistent coagulation reagents, this vulnerability introduces risk across development and manufacturing and makes it harder to ensure reproducibility and compliance.
This raises two important questions: how do these pressures impact IVD assay development, and how can quality, traceability, and sourcing strategy mitigate risk?
What are the risks of coagulation reagent variability?
Many commonly used coagulation reagents, such as rabbit brain cephalin, rabbit brain acetone powder, and acetone powder, are biologically derived and so inherently variable. Stemming from differences in sourcing and processing, as well as lot-to-lot inconsistency, this variability directly impacts assay performance. Changes in reagent composition can affect clotting time measurements in PT and aPTT assays and compromise the reliability of coagulase assays, reducing reproducibility across runs and between batches.
For IVD assay development, this creates significant challenges as validation and lot qualification require a high degree of consistency. Any variability can lead to failed validation runs, repeat testing, and delays in method transfer or scale-up, thereby increasing development timelines and costs.
At the regulatory level, inconsistent reagent performance can trigger audit challenges, additional data requests, and delayed approvals. This introduces unnecessary risk in a landscape where compliance requirements are becoming more stringent.
Ensuring consistency and traceability in every batch
The core solution lies in consistency through controlled quality systems and standardized processes. This consistency begins with standardized sourcing and processing, supported by stringent US standards and a commitment to animal welfare and ethics. Each lot should be tested against defined specifications to confirm performance, with Certificates of Analysis (CoA) and conformity documentation providing formal verification of quality.
Animal Welfare and Ethical Sourcing
Responsible sourcing and humane handling practices are essential to ensure both animal welfare and consistent reagent quality.
Labs should also source from suppliers who implement a robust Quality Management System, such as ISO 9001:2015, to provide a structured framework for ensuring reproducibility and control throughout production. Gaining full visibility into materials and processes supports effective root cause analysis, audit readiness, and regulatory compliance, enabling labs to reduce the risk of revalidation, support QA/RA requirements, and protect assay integrity throughout development and scale-up.
Choosing the right partner for reliable IVD assay development
Selecting the right coagulation reagent manufacturer is a critical step in mitigating risk and ensuring consistent assay performance. Labs should consider a range of criteria when evaluating suppliers (Table 1).
 |
 |
 |
 |
 |
Quality and consistency |
Traceability |
Sourcing and production |
Supply reliability |
Supply chain considerations |
| ISO-certified systems and reliable lot-to-lot performance | Detailed documentation and batch traceability | Standardized, ethical sourcing of biological materials | Ability to deliver consistent volumes and bulk availability to maintain lot consistency | Diversify suppliers where possible and prioritize stable, US-based sourcing to reduce disruption risk |
Table 1: Criteria for evaluating a reliable coagulation reagent manufacturer for IVD assay development
Using these criteria helps identify suppliers that support consistent assay performance, reduce delays in validation and manufacturing, and minimize both operational and regulatory risk.
Coagulation Reagent Manufacturer Checklist
These are the standards we prioritize at Pel-Freez to support consistent outcomes.
Supporting Reliable Assay Development Through Quality and Traceability
Variability in coagulation reagents introduces risk across validation, production, and regulatory compliance. The increasing regulatory pressure and supply instability across the industry only amplify these challenges.
Strong quality systems, full traceability, and reliable sourcing partnerships are essential to mitigating these risks. By prioritizing these elements, organizations can enable more efficient IVD assay development while improving consistency and confidence in results.
Looking to ensure quality and traceability in your supply chain for assay development or diagnostic kit manufacturing? Contact us to discuss your IVD reagent needs.
